-Cell-Specific Glucocorticoid Reactivation Attenuates Inflammatory -Cell Destruction

Citation for published version:

Digital Object Identifier (DOI):
10.3389/fendo.2014.00165

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Frontiers in Endocrinology

Publisher Rights Statement:
Copyright: © 2014 Liu, Turban, Carter, Ahmad, Ramage, Webster, Walker, Seckl and Morton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
β-Cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction

Xiaoxia Liu1,2, Sophie Turban1, Roderick N. Carter1, Shakil Ahmad3, Lynne Ramage1, Scott P. Webster4, Brian R. Walker4, Jonathan R. Seck1 and Nicholas M. Morton1*

1 Molecular Metabolism Group, University/BHF Centre for Cardiovascular Science, Queen’s Medical Research Institute, Edinburgh, UK
2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
3 Aston Medical School, Aston University, Birmingham, UK
4 Endocrinology Unit, University/BHF Centre for Cardiovascular Science, Queen’s Medical Research Institute, Edinburgh, UK

*Correspondence: Nicholas M. Morton, Molecular Metabolism Group, University/BHF Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK. e-mail: nik.morton@ed.ac.uk

Progression and severity of type 1 diabetes is dependent upon inflammatory induction of nitric oxide production and consequent pancreatic β-cell damage. Glucocorticoids (GCs) are highly effective anti-inflammatory agents but have been precluded in type 1 diabetes and in islet transplantation protocols because they exacerbated insulin resistance and suppressed β-cell insulin secretion at the high-doses employed clinically. In contrast, physiological-range elevation of GC action within β-cells ameliorated lipotoxic β-cell failure in transgenic mice overexpressing the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (MIP-HSD11β+ mice). Here, we tested the hypothesis that elevated β-cell 11beta-HSD1 protects against the β-cell destruction elicited by streptozotocin (STZ), a toxin that dose-dependently mimics aspects of inflammatory and autoimmune β-cell destruction. MIP-HSD11β+ mice exhibited an episodic protection from the severe hyperglycemia caused by a single high dose of STZ associated with higher and sustained β-cell survival, maintained β-cell replicative potential, higher plasma and islet insulin levels, reduced inflammatory macrophage infiltration and increased anti-inflammatory T regulatory cell content. MIP-HSD11β+ mice also completely resisted mild hyperglycemia and insulitis induced by multiple low-dose STZ administration. In vitro, MIP-HSD11β+ islets exhibited attenuated STZ-induced nitric oxide production, an effect reversed with a specific 11beta-HSD1 inhibitor. GC regeneration selectively within β-cells protects against inflammatory β-cell destruction, suggesting therapeutic targeting of 11beta-HSD1 may ameliorate processes that exacerbate type 1 diabetes and that hinder islet transplantation.

Keywords: glucocorticoids, 11beta-hydroxysteroid dehydrogenase type 1, type 1 diabetes, inflammation, beta-cells, anti-inflammatory agents, insulin secretion, streptozotocin

INTRODUCTION

Type 1 diabetes is a chronic disease characterized by inflammatory β-cell destruction secondary to an initial autoimmune targeting of the islets (1). Inflammatory macrophages are key to the development and maintenance of islet damage (2). Pro-inflammatory cytokines derived from macrophages and damaged β-cells further suppress β-cell function in part through induction of nitric oxide production (3,4). As type 1 diabetes progresses, pro-inflammatory cytokines inhibit β-cell regeneration, stimulate peripheral insulin resistance and maintain insulin (1).

Glucocorticoids (GCs) are used clinically due to their potent anti-inflammatory and immunosuppressive effects (5) but were excluded as a treatment for type 1 diabetes and in transplant protocols (6) because they promoted peripheral insulin resistance and suppressed β-cell function at the high-doses employed (7–9). However, the prevailing dogma that GC action on β-cells is purely deleterious has been increasingly challenged (10–14). Exposure of normal mouse islets to GCs can improve aspects of secretory function through suppression of inflammatory signaling (10). Moreover, pre-treatment of islets with GCs (11) or localized exposure of transplanted islets to GCs contained within their surrounding implant matrix (12) has shown improved efficacy and graft survival. Crucially, transgenic mice with modest β-cell-specific elevation of the intracellular GC regenerating enzyme 11β-hydroxysteroid dehydrogenase (HSD11b1; 11beta-HSD1; MIP-HSD1 mice) exhibited protection from lipotoxic β-cell failure in vivo as a result of increased islet number, arising from a post-developmental effect, and function, due to enhanced secretory capacity and cell survival signaling (14).

The beneficial effects of β-cell-specific 11beta-HSD1 elevation (14) were manifest in a chronic high-fat feeding obesity model. Although obesity is associated with a low-grade inflammation of the islets (15), the protective mechanisms found in MIP-HSD1 islets were not obviously anti-inflammatory (14). Therefore, the impact of intra-β-cell GC regeneration on the processes of cellular damage occurring in profoundly inflammatory contexts relevant to type 1 diabetes remains unknown. To address this we tested the hypothesis that elevated β-cell 11beta-HSD1 protects against the profound β-cell destruction or inflammatory insulitis driven by distinct doses of the β-cell toxin streptozotocin (STZ).
MATERIALS AND METHODS

ANIMALS
All experiments conformed to local ethical guidelines of the University of Edinburgh and the UK Home Office Animals (Scientific Procedures) Act (1986). Male MIP-HSD1β+/+ and C57BLKS/J (KsJ) littermate control mice (1:4) were housed in standard conditions on a 12 h light/dark cycle and fed standard rodent Chow (Special Diet Services, Edinburgh, UK). Age matched 10–12-week-old male mice were used for all the experiments.

STREPTOZOTOCIN TREATMENTS
Mice were injected intraperitoneally with a single bolus of STZ (180 mg/kg body weight) or for five consecutive days with 40 mg/kg body weight STZ dissolved in 10 mmol/l sodium citrate (pH 4.5) or vehicle. Blood glucose was measured (OneTouch Ultra, Johnson and Johnson, Bucks, UK) from a tail venepuncture. Mice were sacrificed at 3 and 10 days (single dose) or 15 days (multiple dose) after injection. Insulin was measured by ELISA (Crystal Chem, Downers Grove, IL, USA).

IMMUNOHISTOCHEMISTRY
Pancreata were fixed in 4% paraformaldehyde, paraffin embedded, sectioned (4 µm), and immunostained with guinea pig anti-insulin (1:300) (AbCam, Cambridge, UK), rabbit anti-Mac-2 (1:150) (Cedarline, ON, Canada), rabbit anti-FOX3 (1:150) (elixibiose, Hatfield, UK), rabbit anti-NEUROG3 (1:1000), and rabbit anti-SOX9 (1:8000) (Millipore). Islets were incubated with goat anti-rabbit Alexa Fluor 546 (1:200, Molecular probes, Paisley, UK) and DAPI (1:1000, Sigma Aldrich, Dorset, UK) biotinylated anti-guinea pig and anti-rabbit (AbCam) secondary antibodies were used. Image and quantification of positive cells in islet areas were carried out using KS300 software (3.0 CarlZeiss Vision, GBMh) or computerized image analysis (MCID Basic 7.0 software) for analysis of the whole sections. For immunofluorescence, sections were incubated with rabbit anti-ki67 (1:3000, Dakocytomation, Carpinteria, CA, USA) biotinylated anti-guinea pig and anti-rabbit (AbCam) secondary antibodies were used. Image and quantification of positive cells in islet areas were carried out using KS300 software (3.0 CarlZeiss Vision, GBMh) or computerized image analysis (MCID Basic 7.0 software) for analysis of the whole sections. For immunofluorescence, sections were incubated with rabbit anti-ki67 (1:3000, Dakocytomation) then goat anti-rabbit peroxidase (Abcam) followed by Tyramide green 488 (Perkin Elmer, Cambridge, UK) then incubated with rabbit anti-PDX1 (1:1000, Millipore). After antigen retrieval, sections were incubated with goat anti-rabbit Alexa Fluor 546 (1:200, Molecular probes, Paisley, UK) and DAPI (1:1000, Sigma Aldrich, Dorset, UK) and visualized using a Leica fluorescence microscope. Quantification of PDX1 and Ki67 was performed using Image J software (http://www.ncbi.nlm.nih.gov).

ISLET ISOLATION AND PREPARATION
Pancreata were digested with collagenase XI (Sigma Aldrich) and islets were hand-picked under a stereomicroscope in Hank’s Balanced Salt Solution, 10% FBS (Lonza, Berkshire, UK). Batches of 80 islets were incubated in RPMI-1640 ( Gibco, Life Technologies, Paisley, UK), 10% FBS, 6.1 mmol/l D-glucose, 2 mmol/l 11-dehydrocorticosterone with or without 10 mmol/l STZ diluted in sodium citrate 10 mmol/l and with or without L-NAME (Sigma) 5 mmol/l for 72 h on 8 µm inserts (Millipore). Pictures of the islets were taken using a Zeiss microscope and media were collected for measurement of nitric oxide.

NITRIC OXIDE (NO) PRODUCTION
Total NO in the media was assayed as nitrite, the stable breakdown product of NO, using a Sievers chemiluminescence analyzer (Analytix, Sunderland, UK). Islets were homogenized in lysis buffer as described in (14) and protein content evaluated by Biorad assay (BioRad Laboratories, Hercules, CA, USA).

STATISTICS
Data are expressed as mean ± SEM and were analyzed using one-way ANOVA (Newman–Keuls post hoc test).

RESULTS

MIP-HSD1β+/+ MICE RESIST HIGH-DOSE STZ-INDUCED HYPERGLYCEMIA
We began by administering a high-dose of STZ (180 mg/kg body weight) known to completely ablate β-cell function (16). High-dose STZ caused marked and comparable hyperglycemia by 2 days in MIP-HSD1β+/+ and control non-transgenic littermates (KsJ), indicating comparable ablation of β-cell function. However, after day 3, during the inflammatory-response phase of islet destruction, MIP-HSD1β+/+ mice began to exhibit episodic phases of significantly less severe hyperglycemia than KsJ mice (Figures 1A,B) suggestive of partial recovery of function in existing β-cells and/or spontaneous regeneration of new β-cells. Plasma insulin levels were significantly higher in MIP-HSD1β+/+ than in KsJ mice at day 3 and 10 (Figure 1C), consistent with their residual islet insulin staining and further supporting an islet-specific β-cell recovery (Figure 1D). Notably, circulating corticosterone levels were markedly elevated by high STZ, but to a similar degree in KsJ and MIP-HSD1β+/+ mice (nmol/l; KsJ vehicle: 131 ± 28, KsJ high STZ: 355 ± 155, MIP-HSD1β+/+ vehicle: 138 ± 45 MIP-HSD1β+/+ high STZ: 683 ± 125, no significant effect of genotype), supporting a role for local β-cell GC regeneration as the underlying driver of genotype-specific effects.

MIP-HSD1β+/+ MICE MAINTAIN HIGHER β-CELL MASS AND REPLICATIVE CAPACITY AFTER STZ
The remarkable resilience of MIP-HSD1β+/+ β-cells against high-dose STZ could be due to higher β-cell survival or increased spontaneous β-cell regeneration. Of note, there was low and comparable β-cell proliferation (~2% of total islet cell number double-positive for the proliferation marker Ki67 and the β-cell marker PDX1) in vehicle-treated KsJ and MIP-HSD1β+/+ mice (Figure 1A, left lane and quantification Figure 1B), consistent with their residual islet insulin staining and further supporting an islet-specific β-cell recovery (Figure 1D). Despite a marked reduction in PDX1-positive α-cells, a substantial β-cell number remained in STZ-treated MIP-HSD1β+/+ mice, although the comparable hyperglycemia between genotypes from day 2 to 3 indicates these β-cells underwent a period of initial secretory dysfunction (Figure 1). MIP-HSD1β+/+ mice also maintained their Ki67/PDX1 double-positive cell number in their remaining islets (Figure 2A bottom row and quantification Figure 2B) suggesting that their β-cell replicative capacity is maintained after STZ. This could not be accounted for by β-cell neogenesis from potential progenitor cell types, as assessed with SOX9
and NEUROG3 (17, 18) immunostaining that did not differ by genotype 3 or 10 days after STZ (Figures S1 and S2 in Supplementary Material). Apoptosis was not detected in islets of either genotype by a number of methods suggesting that this process does not account for the differences between the genotypes under these experimental conditions (Figure S3 in Supplementary Material).

**MIP-HSD1**<sup>tg/+</sup> ISLETS HAVE REDUCED MACROPHAGE AND INCREASED T REGULATORY CELL INFILTRATION AFTER STZ

Inflammatory macrophage infiltration is an early event in autoimmune (2) and STZ-induced islet damage (19). MIP-HSD1<sup>tg/+</sup> islets had fewer (~40%) infiltrated macrophages, as assessed by the macrophage marker Mac-2, compared to KsJ controls at 3 and 10 days after the single high-dose STZ injection (Figure 3A and quantification, Figure 3B).

T regulatory cells (Treg; FOXP3<sup>+</sup> cells) mediate inflammatory and autoimmune aspects of type 1 diabetes (21, 22), a low-dose of STZ (40 mg/kg/BW) was administered for five consecutive days. KsJ mice showed significant hyperglycemia from day 4 that reached a modestly diabetic plateau by day 12 (Figure 4A), had reduced islet insulin staining (Figure 4B) and increased islet macrophage numbers, whereas MIP-HSD1<sup>tg/+</sup> mice maintained normal glycemia and pancreatic morphology and displayed abrogated macrophage infiltration (Figure 4C, and quantification, Figure 4D).

**MIP-HSD1**<sup>tg/+</sup> MICE RESIST MULTIPLE LOW-DOSE STZ-INDUCED HYPERGLYCEMIA

To test responses to a more subtle diabetic insult that recapitulates some of the inflammatory and autoimmune aspects of type 1 diabetes (21, 22), a low-dose of STZ (40 mg/kg/BW) was administered for five consecutive days. KsJ mice showed significant hyperglycemia from day 4 that reached a modestly diabetic plateau by day 12 (Figure 4A), had reduced islet insulin staining (Figure 4B) and increased islet macrophage numbers, whereas MIP-HSD1<sup>tg/+</sup> mice maintained normal glycemia and pancreatic morphology and displayed abrogated macrophage infiltration (Figure 4C, and quantification, Figure 4D).

**β-CELL glucocorticoids and inflammation**

Inflammatory mediators induce production of nitric oxide (NO) that causes β-cell destruction and acts as an important chemoattractant for macrophages (1, 3, 4). STZ can induce inflammatory pathways and islet damage in part by generating NO (23). Incubation of normal KsJ islets with STZ stimulated NO production (Figure 5A, white bars) and caused islet disintegration (Figure 5C, middle lane, top row). The STZ-induced rise in NO and islet damage was attenuated by the iNOS

---

**FIGURE 1 | MIP-HSD1**<sup>tg/+</sup> mice exhibit episodic improvement in hyperglycemia and higher islet insulin production after high-dose STZ treatment. Twelve-week-old mice were given a single i.p. injection of STZ (180 mg/kg/bodyweight) or citrate buffer as vehicle. (A) Daily blood glucose in littermate vehicle-injected KsJ mice (○, n = 5) and MIP-HSD1<sup>tg/+</sup> mice (▲, n = 7) or after STZ injection in KsJ mice (□), n = 8) and MIP-HSD1<sup>tg/+</sup> mice (■, n = 12). Values represent mean ± SEM, differences were analyzed by one-way ANOVA, Newman–Keuls test, *P < 0.05 and **P < 0.01 for MIP-HSD1<sup>tg/+</sup> STZ vs. KsJ STZ. (B) Area under the curve of overall blood glucose levels in littermate KsJ mice (white bars) and MIP-HSD1<sup>tg/+</sup> mice (black bars). ***P < 0.001 for STZ vs. vehicle, **P < 0.01 for MIP-HSD1<sup>tg/+</sup> STZ vs. KsJ STZ. (C) Plasma insulin at day 0 (before injection) and days 3 and 10 post-STZ injection in littermate KsJ mice (white bars) and MIP-HSD1<sup>tg/+</sup> mice (black bars). ***P < 0.001 and ***P < 0.001 day 3 and 10 vs. day 0. The decrease in plasma insulin was less severe in transgenic mice, **P < 0.01 for day 3 MIP-HSD1<sup>tg/+</sup> STZ vs. day 3 KsJ STZ, **P < 0.01 for day 10 MIP-HSD1<sup>tg/+</sup> STZ vs. day 10 KsJ STZ. (D) Insulin expression shown by immunohistochemical staining of paraffin-fixed pancreata from KsJ littermate (upper row) and MIP-HSD1<sup>tg/+</sup> (lower row) mice after vehicle treatment (veh, left lane) and 3 (middle lane) or 10 days post-STZ treatment (right lane). Bars = 50 µm magnification ×400.
FIGURE 2 | MIP-HSD1<sup>tg/+</sup> mice exhibit enhanced β-cell survival and maintained replicative capacity after STZ treatment. (A) Representative immunofluorescence images of paraffin-fixed pancreata co-stained with rabbit anti-Ki67 (green), rabbit anti-PDX1 (red), and DAPI (blue) from KsJ littermate (upper row), MIP-HSD1<sup>tg/+</sup> (lower row) mice after vehicle treatment (Veh, left lane), 3 (middle lane) and 10 days post-STZ treatment (right lane). Arrows indicate double-positive stained cells, magnification ×400. (B) PDX1 and Ki67 positive cells were counted within the islets as defined morphologically by the islet capsule boundary using Image J software. Proliferating β-cells were measured as a ratio of PDX1, Ki67 double-positive cells over total PDX1-positive cells. Ki67 and PDX1 double-positive staining was undetectable (nd) in KsJ mice 3 and 10 days post-STZ treatment. Values represented mean ± SEM, differences were analyzed by one-way ANOVA, Newman–Keuls test (n = 6–12).

FIGURE 3 | MIP-HSD1<sup>tg/+</sup> mice have reduced islet macrophage infiltration and increased T regulatory cell numbers after STZ administration. (A) Immunohistochemical staining for Mac-2 with (B) quantification and (C) FOXP3 immunohistochemical staining with (D) quantification. (A,C) Pancreata from KsJ littermate (upper rows), MIP-HSD1<sup>tg/+</sup> (lower rows) mice after vehicle (left lane) or 3 (middle lane) and 10 days (right lane) post-STZ treatment were paraffin-fixed and sectioned. (C,D) Mac-2 and FOXP3 positive cells per islet area were quantified using Zeiss (KS300 3.0) software. Values represent mean ± SEM. Differences were analyzed by one-way ANOVA and Newman–Keuls test, *P < 0.05 and ***P < 0.001 for STZ vs. Veh; *P < 0.05 and **P < 0.01 for MIP-HSD1<sup>tg/+</sup> vs. KsJ control; §P < 0.05 and §§§P < 0.001 STZ D10 vs. STZ D3 (n = 6–10). Bars = 50 μm, magnification ×400.

inhibitor, L-NAME (Figures 5A,C, right lane). NO production was suppressed after STZ treatment of MIP-HSD1<sup>tg/+</sup> islets (Figure 5B, black bars) and islet disintegration was attenuated (Figure 5C, middle lane, bottom row). The specific 11beta-HSD1 inhibitor UE2316 (14) reversed suppression of NO found in MIP-HSD1<sup>tg/+</sup> islets in the presence of the 11beta-HSD1 substrate 11-dehydrocorticosterone, confirming that β-cell 11beta-HSD1 activity inhibits NO production.
**DISCUSSION**

Modest elevation of 11beta-HSD1 activity in β-cells (14) has conferred improved β-cell survival and a sustained capacity for spontaneous β-cell regeneration in the context of severe inflammatory β-cell destruction. Although the protection against hyperglycemia is modest across the short-time course of the present studies, the continued survival and replenishment of functional β-cells after high-dose STZ points to a remarkable and unexpectedly effective protective role for local GC regeneration. Hyperglycemia induced by multiple low-dose STZ, a regimen that invokes some effective protective role for local GC regeneration. Hyperglycemia was significantly elevated only KsJ STZ-treated mice. Values represented mean ± SEM. Differences were analyzed by one-way ANOVA, Newman–Keuls test, **P < 0.001 for MIP-HSD1<sup>tg/+</sup> STZ vs. KsJ STZ.**

The protective effect of elevated β-cell 11beta-HSD1 involves both increased β-cell survival and maintained β-cell replicative potential. Improved MIP-HSD1<sup>11β</sup><sup>+/+</sup> islet survival is mediated by GC-mediated suppression of pro-inflammatory NO production (3, 4), an effect of GCs also found in the vasculature (25). Increased expression of heat shock and other cellular stress–resistance pathways in MIP-HSD1<sup>11β</sup><sup>+/+</sup> islets (14) is consistent with their augmented survival, and may counteract triggering of more aggressive inflammatory responses after β-cell insult.

Under normal physiological conditions, β-cell mass is maintained through slow rates of renewal and turnover (26). Hyperglycemia can prompt islet mass compensation predominantly through hypertrophy of existing β-cells (27), β-cell proliferation (26), and neogenesis from progenitors, at least in pancreatic injury models (18). However, we found no evidence for altered ductal (SOX9) or islet endocrine (NEUROG3) progenitor cells as the basis of maintained β-cell mass in STZ-treated MIP-HSD1<sup>11β</sup><sup>+/+</sup> mice, in agreement with recent findings that β-cell neogenesis does not come from ductal cell progenitors in the adult pancreas (17). Thus, altered GC regeneration selectively impacts upon β-cell replication in the STZ-injured adult pancreas. Moreover, MIP-HSD1<sup>11β</sup><sup>+/+</sup> islets exhibit a hyper-functionality associated with increased Cdkn1a (P21) expression suggesting accelerated functional maturation of MIP-HSD1<sup>11β</sup>-cells (14), consistent with the role of GCs in terminal differentiation. Newly generated MIP-HSD1 β-cells likely achieve functionality more rapidly than normal β-cells. In support of this notion, overexpression of the pro-differentiation factor P21 in β-cells promotes resistance to high-dose STZ by increasing progenitor differentiation (28). Notably, apoptosis was undetectable in STZ-treated KsJ mouse islets and pancreas, despite a strong signal in our positive control spleen tissue (Figure S3B in Supplementary Material). It cannot be ruled out that our time points missed a significant incidence of apoptosis, as noted by others (29) or that rapid turnover of apoptotic cells markers [within minutes; (30)] may have caused the signal to fall below our limit of detection. Experimental designs more suited to inducing β-cell apoptosis will be

---

**FIGURE 4 |** MIP-HSD1<sup>11β</sup><sup>+/+</sup> mice completely resist hyperglycemia induced by multiple low-dose injection of STZ. Twelve-week-old mice were injected i.p. either with sodium citrate vehicle or STZ (40 mg/kg body weight) for five consecutive days. (A) Blood glucose levels measured immediately before injections (day 0) and day 4, 8, 12, and 15 after vehicle injection in littermate KsJ mice (■, n = 8) or MIP-HSD1<sup>11β</sup><sup>+/+</sup> mice (●, n = 7) and after STZ injection in littermate KsJ mice (□, n = 8) or MIP-HSD1<sup>11β</sup><sup>+/+</sup> mice (○, n = 12). Blood glucose level in MIP-HSD1<sup>11β</sup><sup>+/+</sup> STZ-treated mice was significantly elevated only KsJ STZ-treated mice. Values represented mean ± SEM. Differences were analyzed by one-way ANOVA, Newman–Keuls test, ***P < 0.001 for MIP-HSD1<sup>11β</sup><sup>+/+</sup> STZ vs. KsJ STZ.

(B) Preservation of islet structure in MIP-HSD1<sup>11β</sup><sup>+/+</sup> shown by insulin staining of paraffin-fixed pancreata from KsJ mice (upper row) and MIP-HSD1<sup>11β</sup><sup>+/+</sup> mice (bottom row) 10 days after the end of vehicle (Veh, left lane) or STZ (right lane) treatment. Scale = 400 μm magnification ×50. (C) Reduced macrophage infiltration in MIP-HSD1<sup>11β</sup><sup>+/+</sup> shown by Mac-2 staining of paraffin-fixed pancreata from KsJ mice (upper row) and MIP-HSD1<sup>11β</sup><sup>+/+</sup> mice (bottom row) 10 days after the end of vehicle (Veh, left lane) or STZ (right lane) treatment. Bars = 50 μm, magnification ×400. (D) Quantitation of Mac-2 positive cells per islet area using Zeiss (KS300, 3.0i) software. Values represent mean ± SEM differences were analyzed by one-way ANOVA, Newman–Keuls test, ***P < 0.001 for STZ vs. Veh; **P < 0.01, ***P < 0.001 for MIP-HSD1<sup>11β</sup><sup>+/+</sup> STZ vs. KsJ STZ (n = 5–10).
needed to determine the contribution of altered β-cell GCs to this process.

Macrophage infiltration in diabetic islets is an early event (1–4). Depletion [19] or inactivation [2] of macrophages prevents the progression of type 1 diabetes, highlighting the importance of the inflammatory mechanism per se in islet destruction. Reduction of macrophage infiltration in MIP-HSD1tg/+ islets is consistent with a reduced inflammatory insult that will work, at least in part, through longer-term curtailment of cytokine-mediated NO generation long after the STZ has been metabolized. GCs suppress a number of distinct pro-inflammatory signaling pathways that will also contribute to overall improvement in islet function (5). The higher Treg cell influx into MIP-HSD1tg/+ mice treated with STZ with or without 11beta-HSD1tg/+ STZ vs. Ksj STZ, **P < 0.01 STZ + L-NAME vs. STZ (n = 6). (B) NO production in media of isolated islets from MIP-HSD1tg/+ mice treated with STZ with or without 11beta-HSD1 inhibitor UE2316 (1 µmol/l) for 72h. Values represent mean ± SEM. Differences analyzed by one-way ANOVA, Newman–Keuls test. **P < 0.01 for STZ vs. Veh; **P < 0.001 for MIP-HSD1tg/+ STZ vs. Ksj STZ, **P < 0.01 STZ + L-NAME vs. STZ (n = 6). (C) Representative light microscopy images of islets from Ksj (upper row) and MIP-HSD1tg/+ mice (lower row) incubated with vehicle (left lane), with STZ (middle lane), or with STZ + L-NAME (right lane). Magnification ×400.

REFERENCES


Conflict of Interest Statement: Scott P. Webster, Brian R, Walker, Jonathan R, Seck, and Nicholas M. Morton hold patents for the use of 1beta-HSD1 inhibitors for metabolic indications. The other coauthors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 29 July 2014; accepted: 25 September 2014; published online: 14 October 2014.


This article was submitted to Genomic Endocrinology, a section of the journal Frontiers in Endocrinology. Copyright © 2014 Liu, Turban, Carter, Ahmad, Ramage, Webster, Walker, Seckl and Morton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.